Open Access. Powered by Scholars. Published by Universities.®
Pharmacy Administration, Policy and Regulation Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Chemicals and Drugs (3)
- Pharmaceutical Preparations (3)
- Health Law and Policy (2)
- Law (2)
- Administrative Law (1)
-
- Cognition and Perception (1)
- Commercial Law (1)
- Food and Drug Law (1)
- Intellectual Property Law (1)
- Mental and Social Health (1)
- Nursing (1)
- Other Nursing (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pediatric Nursing (1)
- Pharmacoeconomics and Pharmaceutical Economics (1)
- Psychology (1)
- Social and Behavioral Sciences (1)
- Substance Abuse and Addiction (1)
- Keyword
-
- Medication (2)
- Pharmaceutical (2)
- ADHD (1)
- Analysis (1)
- Clinical trial (1)
-
- Communication (1)
- Drug (1)
- Drug makers (1)
- Drug trial (1)
- Drugs (1)
- Expert (1)
- FDA (1)
- Initiation (1)
- Innovation (1)
- Innovation policy (1)
- Manufacturing (1)
- Pain medication (1)
- Patents (1)
- Patients (1)
- Physicians (1)
- Policy (1)
- Prescription (1)
- Public (1)
- Quality control (1)
- Regulation (1)
- Regulations (1)
- Restriction (1)
- Risk (1)
- Publication
- Publication Type
Articles 1 - 5 of 5
Full-Text Articles in Pharmacy Administration, Policy and Regulation
Timely Follow Up Care After Initiation Of Adhd Medication In Children: A Quality Improvement Project, Rebecca Haas
Timely Follow Up Care After Initiation Of Adhd Medication In Children: A Quality Improvement Project, Rebecca Haas
DNP Scholarly Projects
Background: Enhancing medication safety, strengthening compliance and mitigating side effects requires close monitoring. A child, defined by Centers for Medicare and Medicaid Services, as being between the ages of 6 years and 12 years of ages, with Attention Deficit Hyperactivity Disorder (ADHD) must have an initial medication visit within 30 days of a first-time trial of ADHD medication. Increasing staff awareness of organizational policy of expected timeframe for medication checks and annotating appointment slots as initial medication checks will decrease the number of days between the first-time trial of ADHD medication and a child’s medication assessment. Methods: The Model for …
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase those …
Book Review, Jennifer L. Frizzell
Book Review, Jennifer L. Frizzell
RISK: Health, Safety & Environment (1990-2002)
Review of the following: THOMAS SZASZ, OUR RIGHT TO DRUGS: THE CASE FOR A FREE MARKET. (Praeger 1992) [164 pp.] Notes, bibliography, name index, notes, preface, subject index. LC: 91-30378; ISBN: 0-275-94216-3. [Cloth $19.95. P.O. Box 5007, Westwood CT 06881-9990.]
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
Risk Perception And Drug Safety Evaluation, Ilan B. Vertinsky, Donald A. Wehrung
RISK: Health, Safety & Environment (1990-2002)
The authors present a Risk communication framework based on a survey of empirical research concerning public Risk perceptions. They also apply it to the area of pharmaceutical regulation to suggest more effective regulatory strategies.
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
Patient Perceptions Of Drug Risks And Benefits, Michael S. Brown, Linda J. Wastila, Carol I. Baras, Louis Lasagna
RISK: Health, Safety & Environment (1990-2002)
This is a report of a pilot study conducted to examine patients' perceptions of drug Risks and benefits. While all of the factors influencing such perceptions are important, the findings about the extent to which views are affected by patient understanding of and confidence in regulatory oversight should be of professional interest to an especially broad audience.